Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Insulet Corporation is a medical device company focused on the development, manufacture, and commercialization of insulin delivery systems for people with diabetes. The company operates within the diabetes medical devices and digital health industries, with a primary emphasis on tubeless insulin pump technology. Its core product is the Omnipod® Insulin Management System, a wearable, disposable insulin delivery device designed to simplify insulin therapy for individuals with Type 1 diabetes and insulin-dependent Type 2 diabetes.
Founded in 2000, Insulet differentiated itself through its tubeless, wearable insulin pump design, which contrasts with traditional tethered pumps. The company’s revenue is primarily driven by recurring sales of disposable pods and associated controller and software ecosystems. Insulet has evolved from an early-stage device innovator into a globally scaled diabetes technology company, benefiting from increased adoption of automated insulin delivery and integration with continuous glucose monitoring (CGM) platforms.
Business Operations
Insulet operates through a single reportable business segment focused on Omnipod® Systems, which includes pod manufacturing, proprietary insulin delivery algorithms, and related software platforms. Revenue is generated primarily through ongoing pod utilization, supplemented by sales of controllers and support services. The company’s model emphasizes recurring consumable revenue, providing predictable cash flows tied to patient usage.
The company conducts manufacturing through a combination of internal facilities and strategic third-party suppliers, with significant investment in automation and quality systems. Insulet maintains commercial operations across the United States, Europe, and other international markets, and collaborates with CGM providers to enable automated insulin delivery functionality. The company does not rely on joint ventures for its core product but maintains technology integration partnerships critical to its ecosystem.
Strategic Position & Investments
Insulet’s strategic direction centers on expanding adoption of its Omnipod® 5 Automated Insulin Delivery System, which integrates insulin delivery with real-time glucose data and algorithm-driven dosing. Growth initiatives include expanding indications for Type 2 diabetes, broadening reimbursement coverage, and increasing international penetration. The company continues to invest heavily in research and development to enhance automation, usability, and digital health integration.
While Insulet has historically pursued organic growth rather than large-scale acquisitions, it has made targeted investments in manufacturing capacity, software development, and data-driven insulin management technologies. The company’s strategy positions it at the intersection of wearable medical devices, connected health, and algorithm-based therapy, aligning with broader trends toward personalized and automated diabetes care.
Geographic Footprint
Insulet is headquartered in Acton, Massachusetts, and operates manufacturing, research, and commercial facilities across North America, Europe, and parts of Asia-Pacific. The United States represents its largest market by revenue, supported by a direct sales force and established reimbursement pathways.
Internationally, Insulet has a growing presence in Western Europe, including the United Kingdom, Germany, France, and Nordic countries, as well as expansion efforts in Canada, Australia, and select Asian markets. The company’s global footprint reflects a strategy of targeting developed healthcare systems with strong diabetes prevalence and reimbursement infrastructure.
Leadership & Governance
Insulet is led by an executive team with experience across medical devices, pharmaceuticals, and healthcare technology. The leadership emphasizes patient-centric design, operational scalability, and disciplined innovation, with a strategic focus on long-term value creation through recurring revenue and technology leadership.
Key executives include:
- Jim Hollingshead – President and Chief Executive Officer
- Wayde McMillan – Chief Financial Officer
- Ashley McEvoy – Chair of the Board of Directors
- Eric Benjamin – Chief Product and Customer Experience Officer
- Michelle Hagen – Chief Human Resources Officer
- Andrew F. Rhodes – Chief Technology Officer